QCB Faculty Dr. Steve Kay Led a Study

QCB faculty Dr. Steve Kay led a study titled “Advancing Clinical Response Against Glioblastoma: Evaluating SHP1705 CRY2 Activator Efficacy in Preclinical Models and Safety in Phase I Trials” published in Neuro-Oncology.  The study shows that, developed in Kay’s lab, novel Cryptochrome (CRY) activator SHP1705, which inhibits BMAL1-CLOCK transcriptional activity, prolongs survival in animal models of glioblastoma, and is safe and well tolerated in humans. Please read the paper here, and USC press release here.